Literature DB >> 17854144

Protective effects of ursodeoxycholic acid on chenodeoxycholic acid-induced liver injury in hamsters.

Tomomichi Iwaki1, Kaoru Ishizaki, Shuji Kinoshita, Hideki Tanaka, Atsushi Fukunari, Makoto Tsurufuji, Teruaki Imada.   

Abstract

AIM: To investigate the effects of ursodeoxycholic acid (UDCA) on chenodeoxycholic acid (CDCA)-induced liver injury in hamsters, and to elucidate a correlation between liver injury and bile acid profiles in the liver.
METHODS: Liver injury was induced in hamsters by administration of 0.5% (w/w) CDCA in their feed for 7 d. UDCA (50 mg/kg and 150 mg/kg) was administered for the last 3 d of the experiment.
RESULTS: At the end of the experiment, serum alanine aminotransferase (ALT) increased more than 10 times and the presence of liver injury was confirmed histologically. Marked increase in bile acids was observed in the liver. The amount of total bile acids increased approximately three-fold and was accompanied by the increase in hydrophobic bile acids, CDCA and lithocholic acid (LCA). UDCA (50 mg/kg and 150 mg/kg) improved liver histology, with a significant decrease (679.3 +/- 77.5 U/L vs 333.6 +/- 50.4 U/L and 254.3 +/- 35.5 U/L, respectively, P < 0.01) in serum ALT level. UDCA decreased the concentrations of the hydrophobic bile acids, and as a result, a decrease in the total bile acid level in the liver was achieved.
CONCLUSION: The results show that UDCA improves oral CDCA-induced liver damage in hamsters. The protective effects of UDCA appear to result from a decrease in the concentration of hydrophobic bile acids, CDCA and LCA, which accumulate and show the cytotoxicity in the liver.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17854144      PMCID: PMC4434625          DOI: 10.3748/wjg.v13.i37.5003

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

1.  Mechanism of cholestasis. 6. Bile acids in human livers with or without biliary obstruction.

Authors:  H Greim; D Trülzsch; P Czygan; J Rudick; F Hutterer; F Schaffner; H Popper
Journal:  Gastroenterology       Date:  1972-11       Impact factor: 22.682

2.  Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease.

Authors:  F Lirussi; A Beccarello; L Bortolato; A M Morselli-Labate; M Crovatto; S Ceselli; G Santini; G Crepaldi
Journal:  Liver       Date:  1999-10

3.  Identification of a nuclear receptor for bile acids.

Authors:  M Makishima; A Y Okamoto; J J Repa; H Tu; R M Learned; A Luk; M V Hull; K D Lustig; D J Mangelsdorf; B Shan
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

4.  Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.

Authors:  P C van de Meeberg; F H Wolfhagen; G P Van Berge-Henegouwen; J M Salemans; A Tangerman; H R van Buuren; J van Hattum; K J van Erpecum
Journal:  J Hepatol       Date:  1996-12       Impact factor: 25.083

5.  Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei.

Authors:  K D Setchell; C M Rodrigues; C Clerici; A Solinas; A Morelli; C Gartung; J Boyer
Journal:  Gastroenterology       Date:  1997-01       Impact factor: 22.682

6.  Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat.

Authors:  R J Sokol; J M McKim; M C Goff; S Z Ruyle; M W Devereaux; D Han; L Packer; G Everson
Journal:  Gastroenterology       Date:  1998-01       Impact factor: 22.682

7.  Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?

Authors:  R Poupon; Y Chrétien; R E Poupon; F Ballet; Y Calmus; F Darnis
Journal:  Lancet       Date:  1987-04-11       Impact factor: 79.321

8.  Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions.

Authors:  D M Heuman
Journal:  J Lipid Res       Date:  1989-05       Impact factor: 5.922

9.  Biliary, fecal and plasma deoxycholic acid in rabbit, hamster, guinea pig, and rat: comparative study and implication in colon cancer.

Authors:  Joelle Kasbo; Myriam Saleem; Shahid Perwaiz; Diane Mignault; Thierry Lamireau; Beatriz Tuchweber; Ibrahim Yousef
Journal:  Biol Pharm Bull       Date:  2002-10       Impact factor: 2.233

10.  A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C.

Authors:  S Takano; Y Ito; O Yokosuka; M Ohto; K Uchiumi; K Hirota; M Omata
Journal:  Hepatology       Date:  1994-09       Impact factor: 17.425

View more
  2 in total

Review 1.  Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed.

Authors:  Michele Pier Luca Guarino; Silvia Cocca; Annamaria Altomare; Sara Emerenziani; Michele Cicala
Journal:  World J Gastroenterol       Date:  2013-08-21       Impact factor: 5.742

2.  BAM8-22 and its receptor MRGPRX1 may attribute to cholestatic pruritus.

Authors:  Babina Sanjel; Han-Joo Maeng; Won-Sik Shim
Journal:  Sci Rep       Date:  2019-07-26       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.